{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:32:08Z","timestamp":1791106328516,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.antiviral.2012.12.023","type":"journal-article","created":{"date-parts":[[2012,12,26]],"date-time":"2012-12-26T15:33:45Z","timestamp":1356536025000},"page":"312-317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Hepatitis B e antigen levels and response to peginterferon: Influence of precore and basal core promoter mutants"],"prefix":"10.1016","volume":"97","author":[{"given":"Milan J.","family":"Sonneveld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Rijckborst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louwerens","family":"Zwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Jenny Heathcote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roeland","family":"Zoutendijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulus S.","family":"Akarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzan D.","family":"Pas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina E.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L.A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2012.12.023_b0005","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2008.05.031","article-title":"Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b","volume":"135","author":"Buster","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2012.12.023_b0010","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1038\/ajg.2009.371","article-title":"Early HBeAg loss during peginterferon alpha-2b therapy predicts HBsAg loss: results of a long-term follow-up study in chronic hepatitis B patients","volume":"104","author":"Buster","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2012.12.023_b0015","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1053\/j.gastro.2009.08.061","article-title":"Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa","volume":"137","author":"Buster","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2012.12.023_b0020","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"Jama"},{"key":"10.1016\/j.antiviral.2012.12.023_b0025","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jviromet.2003.10.002","article-title":"Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay","volume":"115","author":"Deguchi","year":"2004","journal-title":"J. Virol. Meth."},{"key":"10.1016\/j.antiviral.2012.12.023_b0150","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","article-title":"EASL clinical practice guidelines: management of chronic hepatitis B","volume":"50","author":"European Association For The Study Of The","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2012.12.023_b0045","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: incidence and risk factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2012.12.023_b0035","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","article-title":"Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors","volume":"48","author":"Fattovich","year":"2008","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2012.12.023_b0040","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/gut.2007.128496","article-title":"Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years","volume":"57","author":"Fattovich","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2012.12.023_b0050","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1128\/JVI.01902-08","article-title":"A mechanism to explain the selection of the hepatitis e antigen-negative mutant during chronic hepatitis B virus infection","volume":"83","author":"Frelin","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2012.12.023_b0055","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/hep.22065","article-title":"HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B","volume":"47","author":"Fried","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2012.12.023_b0060","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/jmv.21778","article-title":"Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment","volume":"82","author":"Hansen","year":"2010","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2012.12.023_b0065","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2012.12.023_b0075","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2012.12.023_b0070","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/gutjnl-2011-301096","article-title":"Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?","volume":"61","author":"Janssen","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.antiviral.2012.12.023_b0080","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00535-009-0061-7","article-title":"The loss of HBeAg without precore mutation results in lower HBV DNA levels and ALT levels in chronic hepatitis B virus infection","volume":"44","author":"Kawabe","year":"2009","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2012.12.023_b0085","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"Lau","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2012.12.023_b0090","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/hep.24555","article-title":"Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2012.12.023_b0095","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJM199605303342202","article-title":"Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B","volume":"334","author":"Niederau","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2012.12.023_b0100","first-page":"1121","article-title":"Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients","volume":"55","author":"Piratvisuth","year":"2011","journal-title":"Hepatol. Int."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2012.12.023_b0105","first-page":"78","article-title":"Chronic hepatitis B: peginterferon or nucleo(s)tide analogues?","volume":"31","author":"Sonneveld","year":"2010","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2012.12.023_b0110","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/hep.23844","article-title":"Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline","volume":"52","author":"Sonneveld","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2012.12.023_b0130","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2893.2011.01465.x","article-title":"Hepatitis B surface antigen monitoring and management of chronic hepatitis B","volume":"18","author":"Sonneveld","year":"2011","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.antiviral.2012.12.023_b0115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3851\/IMP1887","article-title":"Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-\u03b12b: relation to response and HBV genotype","volume":"17","author":"Sonneveld","year":"2012","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2012.12.023_b0120","doi-asserted-by":"crossref","unstructured":"Sonneveld, M.J., Rijckborst, V., Zeuzem, S., Heathcote, E.J., Simon, K., Senturk, H., Pas, S.D., Hansen, B.E., Janssen, H.L., 2012b. Presence of precore and core promoter mutants limits the probability of response to peginterferon in Hepatitis B e Antigen-positive chronic hepatitis B. Hepatology 56(1), 67\u201375. http:\/\/dx.doi.org\/10.1002\/hep.25636.","DOI":"10.1002\/hep.25636"},{"key":"10.1016\/j.antiviral.2012.12.023_b0125","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1053\/j.gastro.2011.11.025","article-title":"Polymorphisms near IL28B and serological response to peginterferon in HBeAg-positive patients with chronic hepatitis B","volume":"142","author":"Sonneveld","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2012.12.023_b0135","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/hep.23571","article-title":"Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers","volume":"51","author":"Thompson","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2012.12.023_b0140","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/hep.20128","article-title":"Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B","volume":"39","author":"van Zonneveld","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2012.12.023_b0145","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/hep.23568","article-title":"Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B","volume":"51","author":"Wong","year":"2010","journal-title":"Hepatology"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354212003038?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354212003038?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T17:50:11Z","timestamp":1539971411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354212003038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0166354212003038"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2012.12.023","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis B e antigen levels and response to peginterferon: Influence of precore and basal core promoter mutants","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2012.12.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}